Log in

Stemline Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 06/10/2020)
Today's Range
Now: $11.83
50-Day Range
MA: $11.83
52-Week Range
Now: $11.83
Volume1,084 shs
Average Volume1.52 million shs
Market Capitalization$621.21 million
P/E RatioN/A
Dividend YieldN/A
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Read More
Stemline Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:STML



Sales & Book Value

Annual Sales$43.22 million
Book Value$3.26 per share


Net Income$-76,820,000.00
Net Margins-150.30%


Market Cap$621.21 million
Next Earnings DateN/A

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Stemline Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Stemline Therapeutics

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analysts' expectations of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative return on equity of 48.14%.
View Stemline Therapeutics' earnings history

What price target have analysts set for STML?

7 equities research analysts have issued 1-year price targets for Stemline Therapeutics' shares. Their forecasts range from $8.00 to $12.50. On average, they anticipate Stemline Therapeutics' stock price to reach $11.31 in the next twelve months. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for Stemline Therapeutics

Who are some of Stemline Therapeutics' key competitors?

What other stocks do shareholders of Stemline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), FireEye (FEYE), NVIDIA (NVDA) and Sorrento Therapeutics (SRNE).

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the following people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
  • Mr. Robert Francomano, Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno, Sr. VP of Quality & Operations

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $11.83.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $621.21 million and generates $43.22 million in revenue each year. The biopharmaceutical company earns $-76,820,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is www.stemline.com.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.